Ver registro no DEDALUS
Exportar registro bibliográfico

Metrics


Metrics:

Increased iPLA2 activity and levels of phosphorylated GSK3B in platelets are associated with donepezil treatment in Alzheimer’s disease patients (2015)

  • Authors:
  • USP affiliated authors: GATTAZ, WAGNER FARID - FM ; FORLENZA, ORESTES VICENTE - FM
  • USP Schools: FM; FM
  • DOI: 10.1007/s00406-015-0600-6
  • Subjects: DOENÇA DE ALZHEIMER; FÁRMACOS (SISTEMA NERVOSO CENTRAL); PROTEÍNAS QUINASES; FOSFOLIPASES A
  • Language: Inglês
  • Imprenta:
  • Source:
  • Acesso online ao documento

    Online accessDOI or search this record in
    Informações sobre o DOI: 10.1007/s00406-015-0600-6 (Fonte: oaDOI API)
    • Este periódico é de assinatura
    • Este artigo NÃO é de acesso aberto
    • Cor do Acesso Aberto: closed
    Informações sobre o Citescore
  • Título: European Archives of Psychiatry and Clinical Neuroscience

    ISSN: 0940-1334

    Citescore - 2017: 2.93

    SJR - 2017: 1.574

    SNIP - 2017: 1.018


  • Exemplares físicos disponíveis nas Bibliotecas da USP
    BibliotecaCód. de barrasNúm. de chamada
    FM2734912-10BCSEP^160^2015
    How to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      TALIB, L. L.; HOTOTIAN, S. R.; JOAQUIM, H. P. G.; FORLENZA, O. V.; GATTAZ, W. F. Increased iPLA2 activity and levels of phosphorylated GSK3B in platelets are associated with donepezil treatment in Alzheimer’s disease patients. European Archives of Psychiatry and Clinical Neuroscience, Berlin, v. 265, n. 8, p. 701-706, 2015. Disponível em: < http://link.springer.com/article/10.1007/s00406-015-0600-6 > DOI: 10.1007/s00406-015-0600-6.
    • APA

      Talib, L. L., Hototian, S. R., Joaquim, H. P. G., Forlenza, O. V., & Gattaz, W. F. (2015). Increased iPLA2 activity and levels of phosphorylated GSK3B in platelets are associated with donepezil treatment in Alzheimer’s disease patients. European Archives of Psychiatry and Clinical Neuroscience, 265( 8), 701-706. doi:10.1007/s00406-015-0600-6
    • NLM

      Talib LL, Hototian SR, Joaquim HPG, Forlenza OV, Gattaz WF. Increased iPLA2 activity and levels of phosphorylated GSK3B in platelets are associated with donepezil treatment in Alzheimer’s disease patients [Internet]. European Archives of Psychiatry and Clinical Neuroscience. 2015 ; 265( 8): 701-706.Available from: http://link.springer.com/article/10.1007/s00406-015-0600-6
    • Vancouver

      Talib LL, Hototian SR, Joaquim HPG, Forlenza OV, Gattaz WF. Increased iPLA2 activity and levels of phosphorylated GSK3B in platelets are associated with donepezil treatment in Alzheimer’s disease patients [Internet]. European Archives of Psychiatry and Clinical Neuroscience. 2015 ; 265( 8): 701-706.Available from: http://link.springer.com/article/10.1007/s00406-015-0600-6

    Referências citadas na obra
    Leyhe T, Hoffmann N, Stransky E, Laske C (2009) Increase of SCF plasma concentration during donepezil treatment of patients with early Alzheimer’s disease. Int J Neuropsychopharmacol 12(10):1319–1326
    Shen H, Kihara T, Hongo H, Wu X, Kem WR, Shimohama S, Akaike A, Niidome T, Sugimoto H (2010) Neuroprotection by donepezil against glutamate excitotoxicity involves stimulation of alpha7 nicotinic receptors and internalization of NMDA receptors. Br J Pharmacol 161(1):127–139
    Noh MY, Koh SH, Kim SM, Maurice T, Ku SK, Kim SH (2013) Neuroprotective effects of donepezil against Aβ42-induced neuronal toxicity are mediated through not only enhancing PP2A activity but also regulating GSK-3β and nAChRs activity. J Neurochem 127(4):562–574
    Hashimoto M, Kazui H, Matsumoto K, Nakano Y, Yasuda M, Mori E (2005) Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer’s disease? Am J Psychiatry 162(4):676–682
    Talib LL, Diniz BS, Zainaghi IA, Forlenza OV, Gattaz WF (2012) A radioenzymatic assay to identify three groups of phospholipase A(2) in platelets. Prostaglandins Leukot Essent Fatty Acids 86(4–5):149–153
    Schaloske RH, Dennis EA (2006) The phospholipase A2 superfamily and its group numbering system. Biochim Biophys Acta 1761(11):1246–1259 (Review)
    Burke JE, Dennis EA (2009) Phospholipase A2 structure/function, mechanism, and signaling. J Lipid Res 50(Suppl):S237–S242 (Review)
    Dennis EA (1994) Diversity of group types, regulation, and function of phospholipase A2. J Biol Chem 269(18):13057–13060
    Lambeau G, Gelb MH (2008) Biochemistry and physiology of mammalian secreted phospholipases A2. Annu Rev Biochem 77:495–520
    Schaeffer EL, Skaf HD, Novaes Bde A, da Silva ER, Martins BA, Joaquim HD, Gattaz WF (2011) Inhibition of phospholipase A2 in rat brain modifies different membrane fluidity parameters in opposite ways. Prog Neuropsychopharmacol Biol Psychiatry 35(7):1612–1617
    Sun GY, Xu J, Jensen MD, Simonyi A (2004) Phospholipase A2 in the central nervous system: implications for neurodegenerative diseases. J Lipid Res 45(2):205–213
    Schaeffer EL, Forlenza OV, Gattaz WF (2009) Phospholipase A2 activation as a therapeutic approach for cognitive enhancement in early-stage Alzheimer disease. Psychopharmacology 202(1–3):37–51
    Schaeffer EL, da Silva ER, Novaes Bde A, Skaf HD, Gattaz WF (2010) Differential roles of phospholipases A2 in neuronal death and neurogenesis: implications for Alzheimer disease. Prog Neuropsychopharmacol Biol Psychiatry 34(8):1381–1389
    Forlenza OV, Mendes CT, Marie SK, Gattaz WF (2007) Inhibition of phospholipase A2 reduces neurite outgrowth and neuronal viability. Prostaglandins Leukot Essent Fatty Acids 76:47–55
    De-Paula VJ, Schaeffer EL, Talib LL, Gattaz WF, Forlenza OV (2010) Inhibition of phospholipase A2 increases tau phosphorylation at Ser214 in embryonic rat hippocampal neurons. Prostaglandins Leukot Essent Fatty Acids 82:57–60
    Schaeffer EL, Gattaz WF (2005) Inhibition of calcium-independent phospholipase A2 activity in rat hippocampus impairs acquisition of short- and long-term memory. Psychopharmacology 181:392–400
    Schaeffer EL, Gattaz WF (2007) Requirement of hippocampal phospholipase A2 activity for long-term memory retrieval in rats. J Neural Transm 114:379–385
    Schaeffer EL, Zorron PuL, Gagliotti DA, Gattaz WF (2009) Conditioning training and retrieval increase phospholipase A(2) activity in the cerebral cortex of rats. J Neural Transm 116:41–50
    Gattaz WF, Maras A, Cairns NJ, Levy R, Förstl H (1995) Decreased phospholipase A2 activity in Alzheimer brains. Biol Psychiatry 37:13–17
    Gattaz WF, Cairns NJ, Levy R, Förstl H, Braus DF, Maras A (1996) Decreased phospholipase A2 activity in the brain and in platelets of patients with Alzheimer’s disease. Eur Arch Psychiatry Clin Neurosci 246(3):129–131
    Talbot K, Young RA, Jolly-Tornetta C, Lee VM, Trojanowski JQ, Wolf BA (2000) A frontal variant of Alzheimer’s disease exhibits decreased calcium-independent phospholipase A2 activity in the prefrontal cortex. Neurochem Int 37(1):17–31
    Forlenza OV, Wacker P, Nunes PV, Yacubian J, Castro CC, Otaduy MC, Gattaz WF (2005) Reduced phospholipid breakdown in Alzheimer’s brains: a 31P spectroscopy study. Psychopharmacology 180(2):359–365
    Embi N, Rylatt DB, Cohen P (1980) Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. Eur J Biochem 107:519–527
    Chin PC, Majdzadeh N, D’Mello SR (2005) Inhibition of GSK3b is a common event in neuroprotection by different survival factors. Mol Brain Res 137:193–201
    Balaraman Y, Limaye ER, Levey AI, Srinivasan S (2006) Glycogen synthase kinase 3B and Alzheimer’s disease: pathophysiological and therapeutic significance. Cell Mol Life Sci 63:1226–1235
    Jope RS, Yuskaitis CJ, Beurel E (2007) Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochem Res 32:577–595
    Peineau S, Bradley C, Taghibiglou C, Doherty A, Bortolotto ZA, Wang YT et al (2008) The role of gsk-3 in synaptic plasticity. Br J Pharmacol 153(Suppl. 1):S428–S437
    Muyllaert D, Kremer A, Jaworski T, Borghgraef P, Devijver H, Croes S et al (2008) Glycogen synthase kinase-3b, or a link between amyloid and tau pathology? Genes. Brain Behav 7:57–66
    Grimes CA, Jope RS (2001) The multifaceted roles of GSK3b in cellular signaling. Prog Neurobiol 65:391–426
    Gould TD, Manji HK (2005) Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs. Neuropsychopharmacology 30:1223–1237
    Wang QM, Fiol CJ, DePaoli-Roach AA, Roach PJ (1994) Glycogen synthase kinase-3 beta is a dual specificity kinase differentially regulated by tyrosine and serine/threonine phosphorylation. J Biol Chem 269:14566–14574
    Ly PT, Wu Y, Zou H, Wang R, Zhou W, Kinoshita A, Zhang M, Yang Y, Cai F, Woodgett J, Song W (2013) Inhibition of GSK3β-mediated BACE1 expression reduces Alzheimer-associated phenotypes. J Clin Invest 123(1):224–235
    McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 34(7):939–944
    Roth M, Tym E, Mountjoy CQ, Huppert FA, Hendrie H, Verma S, Goddard R (1986) CAMDEX: a standardized Instrument for the diagnosis of mental disorders in the elderly with special reference to early detection of dementia. Br J Psychiatry 149:698–709
    Folstein MF, Folstein SE, McHugh PR (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12(3):189–198
    Talib LL, Yassuda MS, Diniz BS, Forlenza OV, Gattaz WF (2008) Cognitive training increases platelet PLA2 activity in healthy elderly subjects. Prostaglandins Leukot Essent Fatty Acids 78:265–269
    Forlenza OV, Torres CA, Talib LL, de Paula VJ, Joaquim HP, Diniz BS (2011) Increased platelet GSK3B activity in patients with mild cognitive impairment and Alzheimer’s disease. J Psychiatr Res 45(2):220–224
    Diniz BS, Talib LL, Joaquim HPG, De-Paula VRJ, Gattaz WF, Forlenza OV (2011) Platelet GSK3B activity in patients with late-life depression: marker of depressive episode severity and cognitive impairment? World J Biol Psychiatry 12(3):216–222
    Joaquim HP, Talib LL, Forlenza OV, Diniz BS, Gattaz WF (2012) Long-term sertraline treatment increases expression and decreases phosphorylation of glycogen synthase kinase-3B in platelets of patients with late-life major depression. J Psychiatr Res 46(8):1053–1058
    Selkoe DJ (2004) American College of Physicians; American Physiological Society. Alzheimer disease: mechanistic understanding predicts novel therapies. Ann Intern Med 140(8):627–638 (Review)
    Noh MY, Koh SH, Kim Y, Kim HY, Cho GW, Kim SH (2009) Neuroprotective effects of donepezil through inhibition of GSK-3 activity in amyloid-beta-induced neuronal cell death. J Neurochem 108(5):1116–1125
    Gattaz WF, Talib LL, Schaeffer EL, Diniz BS, Forlenza OV (2014) Low platelet iPLA2 activity predicts conversion from mild cognitive impairment to Alzheimer’s disease: a 4-year follow-up study. J Neural Transm 121(2):193–200
    Smesny S, Stein S, Willhardt I, Lasch J, Sauer H (2008) Decreased phospholipase A2 activity in cerebrospinal fluid of patients with dementia. J Neural Transm 115(8):1173–1179
    Akasofu S, Kimura M, Kosasa T, Ogura H, Sawada K (2006) Protective effect of donepezil in primary-cultured rat cortical neurons exposed to N-methyl-d-aspartate (NMDA) toxicity. Eur J Pharmacol 530(3):215–222
    Zhang D, Shooshtarizadeh P, Laventie BJ, Colin DA, Chich JF, Vidic J, de BarryJ Chasserot-Golaz S, Delalande F, Van Dorsselaer A, Schneider F, Helle K, Aunis D, Prévost G, Metz-Boutigue MH (2009) Two chromogranin a-derived peptides induce calcium entry in human neutrophils by calmodulin-regulated calcium independent phospholipase A2. PLoS ONE 4(2):e4501